Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with  a type of blood cancer called myelofibrosis. 

Each year in the UK, over 300 patients are diagnosed with myelofibrosis,  a blood cancer associated with debilitating symptoms including extreme fatigue, pain, weakness and shortness of breath. Around 10-20% of patients go on to develop acute myeloid leukaemia, with median survival from the time of diagnosis just 2 years for patients with high-risk disease.

Stem cell transplant are the only cure for myelofibrosis, but this is only suitable for a small minority of younger patients who don't have other conditions as well. Instead, the standard NHS care for the illness is treatment with a drug called ruxolitnib, but many patients do not respond to this treatment. 

Professor Mead said "The PROMise study is a really exciting study that has just opened in the UK and will be opening across 15 centres. This is introducing a new treatment called PLX2853, in combination with ruxolitininb, for patients with MF (myelofibrosis)."

The impact on patients for this combination of treatments, I hope, will be improvement of their symptoms, improvement of their quality of life, without causing them side effects.
- Professor Adam Mead

The PROMise trial has been launched by Trials Acceleration Programme (TAP), funded by the blood cancer charity Cure Leukaemia. The trial is co-ordinated via the TAP hub at the Cancer Research UK Clinical Trials Unit (CRCTU) and sponsored by the University of Birmingham, and it opened recently at University Hospital of Wales in Cardiff and Nottingham University Hospital.  Along with 13 other NHS centres, University Hospital of Wales and Nottingham University Hospital will recruit  patients with myelofibrosis over the next two years, providing them with the opportunity to take part in a trial that offers a promising alternative to the current standard of care.

Read more about the trial on the Cure Leukaemia website.

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

Survey results: Reconciling work, private and family life during the COVID-19 pandemic at the Radcliffe Department of Medicine

Mark Evans, Joint Chair of the RDM Environment and Culture working group (EACWG), presents the findings of the EACWG Staff Survey, and remembers how it came about in the midst of the pandemic.